<DOC>
	<DOCNO>NCT01525901</DOCNO>
	<brief_summary>The purpose study pilot use Insulin-Like Growth Factor-1 ( IGF-1 ) treatment 22q13 Deletion Syndrome ( Phelan-McDermid Syndrome ) cause SHANK3 gene deficiency order evaluate safety , tolerability , efficacy . IGF-1 injection skin contain human IGF-1 . IGF-1 approve FDA brand name Increlex treatment child short stature due primary IGF-1 deficiency . It use off-label current study FDA approve , yet study human treatment SHANK3 deficiency .</brief_summary>
	<brief_title>Clinical Trial 22q13 Deletion Syndrome ( Phelan-McDermid Syndrome )</brief_title>
	<detailed_description>Overall , 1-3 screen visit , baseline visit study drug first administer , 10 follow-up visit . Follow-up visit occur week 2 , week 4 , week 8 , week 12 treatment phase ( IGF-1 placebo ) , 4 week study completion , Parents/guardians ask administer IGF-1/ placebo injection home also responsible monitor glucose level child . Parents/guardians trained method , schedule phone call appointment dose tolerability discuss . Assessments include follow : - Physical neurological examination - Medical psychiatric history - X-ray long bone ( e.g. , hand ) ensure child 's growth plate close - Electrocardiography - Echocardiography - Pregnancy test applicable - Lab safety measure ( blood draw ) - Autism Diagnostic Interview ( ADI ) - Autism Diagnostic Observation Schedule ( ADOS ) - The Mullen Scales Early Learning Leiter International Performance Scale-Revised - Vineland Adaptive Behavior Scale ( VABS ) - Clinical Global Impressions ( CGI ) Rating Scales - The Repetitive Behaviors Scale ( RBS ) - Aberrant Behavior Checklist ( ABC ) - The Caregiver Strain Questionnaire ( CSI ) - Language Environment Analysis ( LENA ) - The Macarthur-Bates Communication Inventory ( MCDI ) - Unified Parkinson 's Disease Rating Scale ( UPDRS ) - Quick Neurological Screening Test 2nd Edition ( QNST-2 ) - Gait Analysis motion capture video system interactive 3-dimensional modeling system</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Chromosome Deletion</mesh_term>
	<mesh_term>Chromosome Disorders</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>5 12 year old pathogenic deletion mutation SHANK3 gene stable medication regimen least three month prior enrollment closed epiphysis active suspect neoplasia intracranial hypertension hepatic insufficiency renal insufficiency cardiomegaly / valvulopathy history allergy IGF1 component formulation ( mecasermin ) history extreme prematurity ( &lt; 1000 gram ) associate early neonatal complication , e.g . intracerebral hemorrhage , prolong hypoxia , prolong hypoglycemia patient comorbid condition deem medically compromise tolerate risk experimental treatment IGF1</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>SHANK3</keyword>
	<keyword>IGF-1</keyword>
	<keyword>Autism</keyword>
</DOC>